written on 12.03.2014

Alexion raises guidance as French HTA says yes to Soliris

TAGS: ,

Alexion Pharmaceuticals has revised its previously stated 2014 guidance following successful discussions with the French reimbursement authority concerning its orphan drug Soliris (eculizumab).